VolitionRx Limited (VNRX)

ASE – Real vaqt narxi. Valyuta: USD

2.32

+0.27 (13.17%)

Yopilishda: May 12, 2026, 4:00 PM EDT

06.05.2026

VolitionRx Announces Submission of Manuscript for Nu.Q® Vet Cancer Test in Cats

The publication of this study in a peer reviewed journal is expected subsequently to unlock a $5 million contractual milestone payment HENDERSON, Nev., May 6, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announces submission for peer review a clinical manuscript1 reporting the high accuracy of its Nu.Q® Vet Feline prototype assay in detecting lymphoma in cats, the most common cancer in the species2.

29.04.2026

Volition Announces Breakthrough Finger-Prick Detection of Nucleosomes; Expanding Global Market Potential for Sepsis Testing

HENDERSON, Nev., April 29, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces a major technical milestone with the successful detection of nucleosomes in capillary blood from critically ill sepsis patients using its lateral flow prototype.

23.04.2026

VolitionRx Announces Acceptance of Compliance Plan by NYSE American

HENDERSON, Nev., April 23, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition" or the "Company"), a multi-national epigenetics company, announced today that on April 22, 2026, the NYSE American LLC (the "NYSE American") accepted the Company's plan of compliance for continued listing on the exchange.

20.04.2026

Volition Launches rNuQ™ Webshop Broadening Product Range

HENDERSON, Nev., April 20, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announces the launch of its rNuQ webshop offering a range of reliable, ready to use recombinant nucleosomes that we have developed over the past 10 years.

01.04.2026

VolitionRx Limited (VNRX) Q4 2025 Earnings Call Transcript

31.03.2026

VolitionRx Limited Announces Full Fiscal Year 2025 Financial Results and Business Update

Conference call to discuss financial and operational results scheduled for Wednesday, April 1 at 8:30 a.m. U.S. Eastern Time HENDERSON, Nev.

31.03.2026

VolitionRx Secures EUR 2.0 Million of Non-Dilutive Funding from Regional Government Agencies in Belgium

HENDERSON, Nev., March 31, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, has secured an additional €2.0 million (approximately $2.3 million) in financing from Namur Invest ("NI") and Wallonie Entreprendre S.A.

Videolar

No Data

There is no data to display

Press-relizlar

06.05.2026

VolitionRx Announces Submission of Manuscript for Nu.Q® Vet Cancer Test in Cats

29.04.2026

Volition Announces Breakthrough Finger-Prick Detection of Nucleosomes; Expanding Global Market Potential for Sepsis Testing

23.04.2026

VolitionRx Announces Acceptance of Compliance Plan by NYSE American

20.04.2026

VolitionRx Limited (VNRX)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

VolitionRx Limited (VNRX)

VolitionRx Announces Submission of Manuscript for Nu.Q® Vet Cancer Test in Cats

Volition Announces Breakthrough Finger-Prick Detection of Nucleosomes; Expanding Global Market Potential for Sepsis Testing

VolitionRx Announces Acceptance of Compliance Plan by NYSE American

Volition Launches rNuQ™ Webshop Broadening Product Range

VolitionRx Limited (VNRX) Q4 2025 Earnings Call Transcript

VolitionRx Limited Announces Full Fiscal Year 2025 Financial Results and Business Update

VolitionRx Secures EUR 2.0 Million of Non-Dilutive Funding from Regional Government Agencies in Belgium

Videolar

No Data

Press-relizlar

VolitionRx Announces Submission of Manuscript for Nu.Q® Vet Cancer Test in Cats

Volition Announces Breakthrough Finger-Prick Detection of Nucleosomes; Expanding Global Market Potential for Sepsis Testing

VolitionRx Announces Acceptance of Compliance Plan by NYSE American

Volition Launches rNuQ™ Webshop Broadening Product Range

VolitionRx Announces Submission of Manuscript for Nu.Q® Vet Cancer Test in Cats

Volition Announces Breakthrough Finger-Prick Detection of Nucleosomes; Expanding Global Market Potential for Sepsis Testing

VolitionRx Announces Acceptance of Compliance Plan by NYSE American

Volition Launches rNuQ™ Webshop Broadening Product Range

VolitionRx Limited (VNRX) Q4 2025 Earnings Call Transcript

VolitionRx Limited Announces Full Fiscal Year 2025 Financial Results and Business Update

VolitionRx Secures EUR 2.0 Million of Non-Dilutive Funding from Regional Government Agencies in Belgium

Videolar

No Data

Press-relizlar

VolitionRx Announces Submission of Manuscript for Nu.Q® Vet Cancer Test in Cats

Volition Announces Breakthrough Finger-Prick Detection of Nucleosomes; Expanding Global Market Potential for Sepsis Testing

VolitionRx Announces Acceptance of Compliance Plan by NYSE American

Volition Launches rNuQ™ Webshop Broadening Product Range

Search stocks

VolitionRx Limited (VNRX)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

VolitionRx Limited (VNRX)

VolitionRx Announces Submission of Manuscript for Nu.Q® Vet Cancer Test in Cats

Volition Announces Breakthrough Finger-Prick Detection of Nucleosomes; Expanding Global Market Potential for Sepsis Testing

VolitionRx Announces Acceptance of Compliance Plan by NYSE American

Volition Launches rNuQ™ Webshop Broadening Product Range

VolitionRx Limited (VNRX) Q4 2025 Earnings Call Transcript

VolitionRx Limited Announces Full Fiscal Year 2025 Financial Results and Business Update

VolitionRx Secures EUR 2.0 Million of Non-Dilutive Funding from Regional Government Agencies in Belgium

Videolar

No Data

Press-relizlar

VolitionRx Announces Submission of Manuscript for Nu.Q® Vet Cancer Test in Cats

Volition Announces Breakthrough Finger-Prick Detection of Nucleosomes; Expanding Global Market Potential for Sepsis Testing

VolitionRx Announces Acceptance of Compliance Plan by NYSE American

Volition Launches rNuQ™ Webshop Broadening Product Range

VolitionRx Announces Submission of Manuscript for Nu.Q® Vet Cancer Test in Cats

Volition Announces Breakthrough Finger-Prick Detection of Nucleosomes; Expanding Global Market Potential for Sepsis Testing

VolitionRx Announces Acceptance of Compliance Plan by NYSE American

Volition Launches rNuQ™ Webshop Broadening Product Range

VolitionRx Limited (VNRX) Q4 2025 Earnings Call Transcript

VolitionRx Limited Announces Full Fiscal Year 2025 Financial Results and Business Update

VolitionRx Secures EUR 2.0 Million of Non-Dilutive Funding from Regional Government Agencies in Belgium

Videolar

No Data

Press-relizlar

VolitionRx Announces Submission of Manuscript for Nu.Q® Vet Cancer Test in Cats

Volition Announces Breakthrough Finger-Prick Detection of Nucleosomes; Expanding Global Market Potential for Sepsis Testing

VolitionRx Announces Acceptance of Compliance Plan by NYSE American

Volition Launches rNuQ™ Webshop Broadening Product Range